文献速递骨质疏松与代谢性骨病

阿仑膦酸在肾功能减退老年患者中的应用:临床实践中的挑战与机会

Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice.
PubMed 文献 · Osteoporos Int · 2021-03-15

这项回顾性队列研究纳入了肌酐清除率低于35ml/min的老年骨质疏松患者,比较使用阿仑膦酸与仅补钙/维生素D的保守治疗。结果显示阿仑膦酸未导致肾功能显著恶化,骨质疏松性骨折或急性肾损伤发生率无统计学显著差异。

要点

  • 肌酐清除率<35ml/min的老年患者使用阿仑膦酸未观察到肾功能显著恶化。
  • 阿仑膦酸组与保守治疗组的骨质疏松性骨折发生率无统计学显著差异。
  • 急性肾损伤发生率在阿仑膦酸组与保守组间无显著差异。

核心结论

  • 在肌酐清除率<35ml/min的患者中,阿仑膦酸治疗与基线肾功能显著恶化无关。
  • 尽管研究对次要结局的检验效能不足,各组间骨质疏松性骨折或急性肾损伤发生率无统计学显著差异。

研究设计与样本

  • 回顾性队列研究,纳入肌酐清除率<35ml/min使用阿仑膦酸者98例(A组)、肌酐清除率<35ml/min保守治疗者96例(B组)、肌酐清除率≥35ml/min使用阿仑膦酸者96例(C组),随访至22个月。

主要发现

  • A组肌酐清除率较基线变化为-1.53±6.83ml/min,B组为0.59±5.17ml/min,两组比较p=0.075。
  • A组与C组(-3.71±7.54ml/min)比较p=0.163。
  • A组与B组骨质疏松性骨折调整相对风险aRR 2.02(95%CI 0.64-6.37)。
  • A组与C组骨质疏松性骨折aRR 1.15(95%CI 0.46-2.89)。
  • A组与B组急性肾损伤aRR 0.48(95%CI 0.20-1.12);A组与C组急性肾损伤RR 7.84(95%CI 0.98-62.66)。

临床怎么用

  • 对于肌酐清除率<35ml/min的老年骨质疏松患者,阿仑膦酸治疗未显示显著肾功能恶化,但需注意研究对次要结局效能不足。

局限性

  • 研究对次要结局的检验效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In this retrospective cohort study, alendronate use among older osteoporosis patients (age>65 years) with reduced renal function (creatinine clearance<35ml/min) was not associated with significant deterioration in renal function from baseline nor increased incidence of osteoporotic fractures or acute kidney injury, compared with patients conservatively managed with only calcium/vitamin D supplementation. INTRODUCTION: Oral bisphosphonates are not recommended in patients with creatinine clearance (CrCl) <35ml/min, although this is not supported by post hoc analyses of pivotal oral bisphosphonate studies. As both osteoporosis and renal insufficiency are more prevalent with advancing age, it is important to determine the safety and efficacy of oral bisphosphonates among these patients. METHODS: Patients with CrCl <35ml/min on alendronate (group A, n=98), with CrCl <35ml/min conservatively managed (group B, n=96), and with CrCl ≥35ml/min on alendronate (group C, n=96) were followed up to 22 months. Primary outcomes were mean change in CrCl from baseline in group A compared with groups B and C, respectively. Secondary outcomes were the incidence of osteoporotic fractures and adverse events between groups. RESULTS: There was no significant change in CrCl from baseline when comparing group A (-1.53±6.83ml/min) with group B (0.59±5.17ml/min) (p=0.075), and group A with group C (-3.71±7.54ml/min) (p=0.163). There was no significant increase in incidences of osteoporotic fractures in group A compared with group B (adjusted relative risk (aRR) 2.02, 95% confidence interval (CI) 0.64-6.37) and group A compared with group C (aRR 1.15, 95% CI 0.46-2.89). There was no significant difference in incidences of acute kidney injury (AKI) in group A compared with group B (aRR 0.48, 95% CI 0.20-1.12). Although statistically non-significant, there was an increase in AKI incidence in group A compared with group C (RR 7.84, 95% CI 0.98-62.66). CONCLUSION: Among patients with CrCl <35ml/min, alendronate therapy was not associated with significant deterioration in renal function from baseline. Although not powered for secondary outcomes, there were no statistically significant differences in osteoporotic fracture or AKI incidence between the groups.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Naganathar N, Yau W-, Mok ZH, et al. Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice. Osteoporos Int. 2021. PMID: 33721033. doi:10.1007/s00198-021-05907-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。